黄芪注射液治疗子宫内膜肿瘤临床疗效及对患者肿瘤标志物血清CA125、HE4影响的研究

Effect of Huangqi injection on the clinical effect of endometrial carcinoma and the effect of the serum CA125 and HE4 on the tumor markers

目的:分析黄芪注射液治疗子宫内膜肿瘤患者临床疗效,及对患者血清肿瘤标志物癌胚抗原125(CA125)、人附睾分泌蛋白4(HE4)的影响。方法:选择我院收治的子宫内膜癌患者124例作为研究对象,所有患者均行保守治疗。将患者分为对照组和观察组两组,每组患者62例。两组患者均行化疗,观察组在化疗基础上再予以黄芪注射液治疗,两组患者均完成既定化疗方案和疗程。比较两组患者化疗前、化疗后血清肿瘤标志物CA125、HE4、T淋巴细胞亚群(CD_3^+、CD_4^+、CD_8^+、CD_4^+/CD_8^+)变化,两组患者完成化疗后采用新的实体瘤疗效评价标准(RECIST)对临床疗效判定。收集并比较两组患者化疗过程中毒副反应情况。结果:完成一个疗程后,对照组患者血清CA125、HE_4、CD_3^+、CD_4^+、CD_4^+/CD_8^+较治疗前有所下降,但差异均无统计学意义(P>0.05),观察组患者CA125、HE4较治疗前下降显著,CD_3^+、CD_4^+、CD_4^+/CD_8^+较治疗前明显升高(P<0.05),两组患者CD_8^+治疗前后比较差异无统计学意义(P>0.05)。观察组患者完成疗程后,RE-CIST疗效结果比较,观察组患者PD率明显低于对照组、CR率、总有效率明显高于对照组(P<0.05)。两组患者化疗过程中,观察组患者毒副反应率明显低于对照组(P<0.05)。结论:黄芪注射液辅助子宫内膜癌患者保守治疗,可有效促进患者免疫功能、降低化疗毒副反应、提升化疗治疗效果,对治疗子宫内膜癌患者具有较高的临床价值。

Objective：To analyze the clinical efficacy of Huangqi injection in the treatment of endometrial cancer,and the effects of serum tumor markers,carcinoembryonic antigen 125（CA125）and human epididymal secretory protein 4（HE4）.Methods：124cases of endometrial cancer admitted to our hospital were selected as the research subjects.All the patients did not conform to the indications of surgical treatment.They all received conservative treatment.The patients were divided into two groups,the control group and the observation group,with 62cases in each group.The two groups of patients were treated with chemotherapy,and the observation group was treated with Huangqi injection on the basis of chemotherapy,and the two groups all completed the established chemotherapy scheme and course of treatment.Patients in two groups before and after chemotherapy,the serum tumor markers CA（125）,HE4,T lymphocyte subsets two groups of patients after chemotherapy by response evaluation criteria in solid tumors（RECIST）of the new low standard patients clinical curative effect judgment.the side effects of the two groups of patients with chemotherapy were collected and compared.Results：There was no significant difference in serum CA（125）,HE4,CD3-＋,CD4-＋,CD8-＋and CD4-＋/CD8-＋in the two groups before entering the group（P〉0.05）.After the treatment,the patients in the observation group CA（125）,HE4decreased significantly,CD3-＋,CD4-＋,CD4-＋and/CD8-＋significantly increased（P〈0.05）,there was no significant difference between the two groups of patients before and after CD8-＋treatment（P〉0.05）.After the observation group completed the course oftreatment,the results of RECIST efficacy.The rate of PD in the observation group was significantly lower than that in the control group（P〈0.05）.In the two groups of patients with chemotherapy,the rate of side reaction in the observation group was significantly lower than that of the control group（P〈0.05）.Conclusion：Huangqi injection adjuvant treatment of endometrial cancer patients can effectively promote the immune function,reduce the side effects of chemotherapy,improve the effect of chemotherapy,and has a high clinical mechanism for the treatment of endometrial cancer.